November 1, 2010EuroIntervention
Impact of treatment choice on the outcome of patients proposed for transcatheter aortic valve implantation
Key result
TAVI was associated with lower 6-month cardiac mortality compared to medical management and BAV (6-month freedom from cardiac death 92.0% for TAVI vs 72.7% for MM and 72.9% for BAV).
Why the study?
Does TAVI improve 6-month cardiac mortality compared to SAVR, BAV, or medical management in patients with severe aortic stenosis at high surgical risk?
Population
166 consecutive patients with severe aortic stenosis at high surgical risk referred for TAVI
Comparison
Transcatheter aortic valve implantation with the… vs Surgical aortic valve replacement, balloon…
Design
Cohort
Follow-up
median 9 months (IQR 4.5-12.4 months)
Authors
Discussion
Loading...
Member takes
Implication
TAVI may lower 6-month cardiac mortality versus BAV or MM in high-risk AS; leaves open randomized comparison with SAVR.
Study Design
Type
Cohort (n=166)
Multicenter
Yes
Structured PICO
Does TAVI improve 6-month cardiac mortality compared to SAVR, BAV, or medical management in patients with severe aortic stenosis at high surgical risk?
P
Population
166 consecutive patients with severe aortic stenosis at high surgical risk referred for TAVI, followed for a median of 9 months.
E
Exposure
Transcatheter aortic valve implantation (TAVI) with the CoreValve prosthesis
C
Comparator
Surgical aortic valve replacement (SAVR), balloon aortic valvuloplasty (BAV), or medical management (MM)
O
Outcome
6-month cardiac mortalityhard clinical
Main Result
Absolute Event Rate: 92% vs 72.7%
In high-risk patients with severe aortic stenosis, TAVI was associated with lower 6-month cardiac mortality compared to medical management or BAV, and had similar outcomes to SAVR.
Cite This Study
Carlo et al. (2010) conducted a cohort in severe aortic stenosis at high surgical risk (n=166). Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement (SAVR), balloon aortic valvuloplasty (BAV), or medical management (MM) was evaluated on 6-month cardiac mortality (reported as 6-month freedom from cardiac death). TAVI was associated with lower 6-month cardiac mortality compared to medical management and BAV (6-month freedom from cardiac death 92.0% for TAVI vs 72.7% for MM and 72.9% for BAV).